Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK And SuperGen In Epigenetics Pact
by Ann M. Thayer
November 2, 2009
| A version of this story appeared in
Volume 87, Issue 44
GlaxoSmithKline and SuperGen will work together to discover cancer therapies based on epigenetic, or gene expression, targets. Epigenetic processes, in which gene regulation is altered without changes to the underlying DNA, are believed to play a role in the development and progression of most cancers. GSK will pay SuperGen $5 million up front, including the purchase of $3 million in stock, and potentially up to $375 million in milestone payments. After SuperGen advances compounds to the early clinical proof-of-concept stage, GSK has the right to further develop and commercialize them.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X